February 26, 2020 / 12:53 PM / a month ago

BRIEF-Actinium Pharmaceuticals Says Actimab-A Being Studied In A Phase 1 Combination With Bcl-2 Inhibitor In Patients With Relapsed Or Refractory AML

Feb 26 (Reuters) - Actinium Pharmaceuticals Inc:

* ACTINIUM ANNOUNCES ACTIMAB-A PLUS 7+3 COMBINATION TRIAL FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS

* ACTINIUM PHARMACEUTICALS - ACTIMAB-A BEING STUDIED IN A PHASE 1 COMBINATION WITH BCL-2 INHIBITOR IN PATIENTS WITH RELAPSED OR REFRACTORY AML Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below